Angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs) [1,2,3], and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) [15,16,17] have significantly reduced the incidence of CV death, particularly from progressive HF and sudden death, with no impact on death from non-CV causes. This evidence concerns the gene NR3C2 and hydrops fetalis.